Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor

Status:
Recruiting

Trial end date:
2024-03-01

Target enrollment:

Participant gender:

Phase 2 study of the safety, tolerability, PK, and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.